Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New central dopamine agonists.

J Borsy

    Polish Journal of Pharmacology and Pharmacy
    |May 1, 1985
    PubMed
    Summary
    This summary is machine-generated.

    A novel ergot derivative, GYKI-32 887, shows potent dopamine receptor agonist activity. This compound demonstrates superior efficacy in inhibiting prolactin secretion and treating parkinsonism compared to bromocriptine.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Preclinical studies with compound GYKI-22441, a new long-acting neuroleptic phenothiazine.

    Acta physiologica Hungarica·1990
    Same author

    Anti-amnesic effect of a thiazolidine compound, GYKI-20 238.

    Acta physiologica Hungarica·1990
    Same author

    Effect of amprilose on various immunological and inflammatory animal models.

    Acta physiologica Hungarica·1990
    Same author

    Neuropharmacology of a new psychotropic 2,3-benzodiazepine.

    Arzneimittel-Forschung·1987
    Same author

    The effect of GYKI-32 887 on dopamine (D2) and serotonin (5-HT1 and 5-HT2) receptors.

    Polish journal of pharmacology and pharmacy·1985
    Same author

    The role of central dopamine (DA) receptors in the regulation of blood pressure.

    Polish journal of pharmacology and pharmacy·1985
    Same journal

    Melatonin in vertebrate retina: biosynthesis, receptors and functions.

    Polish journal of pharmacology and pharmacy·1992
    Same journal

    Circadian changes in the elimination of amitriptyline in rats.

    Polish journal of pharmacology and pharmacy·1992
    Same journal

    Circadian variations of phenacetin metabolism in rats in vivo and in vitro.

    Polish journal of pharmacology and pharmacy·1992
    Same journal

    Circadian changes of cytochrome P-450-dependent monooxygenase system in the rat liver.

    Polish journal of pharmacology and pharmacy·1992
    Same journal

    The role of GABA-ergic signal in the regulation of melatonin biosynthesis in vertebrate retina.

    Polish journal of pharmacology and pharmacy·1992
    Same journal

    Structure-activity relationship studies of CNS agents. Part VIII. Bulk tolerance around the protonation center of 4-substituted 1-(3-chlorophenyl)piperazines at 5-HT1A and 5-HT2 receptors.

    Polish journal of pharmacology and pharmacy·1992
    See all related articles

    Area of Science:

    • Neuroscience
    • Pharmacology
    • Endocrinology

    Background:

    • Dopamine receptor agonists are crucial for treating parkinsonism, endocrine, and cardiovascular diseases.
    • Ergot derivatives like bromocriptine are established therapies.
    • Research focuses on developing novel dopamine agonists with improved efficacy.

    Purpose of the Study:

    • To evaluate the endocrinological effects and dopamine receptor stimulant activity of novel elymoclavine derivatives.
    • To identify the most potent dopamine agonist for preclinical investigation.
    • To compare the efficacy of GYKI-32 887 with existing treatments like bromocriptine.

    Main Methods:

    • Synthesis of semi-synthetic elymoclavine derivatives.
    • Examination of central and peripheral dopamine transmission.

    Related Experiment Videos

  • Assessment of prolactin secretion inhibition and antiparkinsonian efficacy.
  • Evaluation of bicuculline-induced convulsion inhibition.

    • Main Results:

    • Compound GYKI-32 887 emerged as the most effective dopamine agonist among synthesized derivatives.
    • GYKI-32 887 demonstrated greater potency than bromocriptine in inhibiting prolactin secretion.
    • GYKI-32 887 exhibited superior antiparkinsonian efficacy compared to bromocriptine.
    • Unlike bromocriptine, GYKI-32 887 inhibited bicuculline-induced convulsions, suggesting GABA receptor agonistic effects.

    Conclusions:

    • GYKI-32 887 is a highly potent dopamine receptor agonist with significant therapeutic potential.
    • Its superior efficacy over bromocriptine in prolactin inhibition and antiparkinsonian effects warrants further investigation.
    • The observed GABA receptor agonistic activity suggests potential applications in treating dyskinesias.